Global Pharmatech Receives SFDA Clinical Approval For New Drug Form of YanLiXiao JILIN, China, June 22 /Xinhua-PRNewswire/ -- Global Pharmatech, Inc. (OTC Pink Sheets: GBLP), a company which combines R&D of botanical drug products, manufacturing, and sales and marketing for the Over-the-Counter (OTC) and prescription drug markets, announced that Jilin BCT Pharmacy Co. Ltd., a subsidiary of Global Pharmatech, has just received Investigational New Drug (IND) approval for its re-formulated herbal drug product, the YanLiXiao pill, from the State Food and Drug Administration (SFDA) of China, Chinese regulatory authority. The Company will soon commence clinical development of the YanLiXiao pill. YanLiXiao is used for the treatment of acute dysentery, enteritis, acute and chronic tonsillitis, and upper-airway infections. This product has traditionally been in capsule and regular tablet forms, and has been used clinically for over 20 years with an annual sale of more than RMB 500 million. The newly developed YanLiXiao pill is formulated by using nine kinds of Chinese medical herbal materials. Dr. Sun Xiaobo, President and CEO of Global Pharmatech, commented, "We have high expectations for our re-formulated YanLiXiao pill. The pill is more effective than its capsule and regular tablet counterparts with advanced technology allowing for smaller dosage and convenient consumption. We are confident that the new YanLiXiao pill formulation will gradually take over market share from the traditional YanLiXiao forms. Global Pharmatech continues to strive for innovative methods in providing the most effective herbal drug products in easy-to-consume forms to the global mainstream marketplace." Jilin BCT Pharmacy has already filed for patent protection for its YanLiXiao pill formulation with the State Intellectual Property Office of China. ABOUT GLOBAL PHARMATECH Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine while utilizing modern facilities and advanced R&D technologies. Global Pharmatech offers a full range of "start to finish" biotech services, from R&D and testing, to manufacturing drugs in liquid and solid dose forms, to sales and marketing. Global Pharmatech utilizes unique extraction methods and innovative techniques that have been developed by its R&D team. Global Pharmatech's core business to date has been licensing its R&D patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution in China, Malaysia, Singapore and Indonesia. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. Contact: Brandi Piacente Investor Relations The Anne McBride Co. 212-983-1702 x208 Email: DATASOURCE: Global Pharmatech CONTACT: Brandi Piacente, Investor Relations for The Anne McBride Co., +1-212-983-1702, ext. 208,

Copyright